A multi-center prospective observational clinical study to evaluate HF10™ therapy in patients with chronic intractable predominant leg pain

evro Corp0 sites90 target enrollmentFebruary 24, 2017

Overview

No summary available.

Registry

who.int

Start Date

February 24, 2017

End Date

October 31, 2021

Last Updated

4 years ago

Study Type

Observational

Sex

All

Sponsor

evro Corp

•1\. Predominant leg pain either idiopathic in origin or from failed back surgery syndrome which has been refractory to conservative therapy for a minimum of 3 months
•2\. Average leg pain intensity of \= 5 out of 10 cm on the Visual Analog Scale (VAS) at enrollment
•3\. Average leg pain intensity \> average back pain intensity on the Visual Analog Scale (VAS) by 2 cm at enrollment
•4\. Neuropathic pain as clinically determined by the investigator
•5\. On stable pain medications, as determined by the Investigator, for at least 4 weeks prior to the Baseline Visit
•6\. Be an appropriate candidate for HF10 therapy
•7\. At least 18 years of age at time of enrollment
•8\. Willing and capable of giving written informed consent prior to any study \-related assessment
•9\. Was evaluated at the investigational site at least once prior to screen for the pain condition related to the study
•10\. Willing and able to comply with study\-related requirements, assessments and visits

•1\. A medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study assessments, accurate pain reporting, and/or confound evaluation of study endpoints
•2\. Evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcome, as determined by the investigator in consultation with a clinical psychologist if applicable
•3\. A current diagnosis of a progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, rapidly progressive diabetic peripheral neuropathy, brain or spinal cord tumor, or severe/critical spinal stenosis
•4\. A visceral pain in the area being treated
•5\. A current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease or uncontrolled diabetes mellitus
•6\. A diagnosis of scoliosis that precludes lead placement
•7\. Leg pain that occurs only with weight bearing
•8\. Benefitting within 30 days prior to enrollment from an interventional procedure and/or surgery to treat back and/or leg pain
•9\. Existing drug pump and/or SCS system or another active implantable device such as a pacemaker (switched On or Off)
•10\. Have a condition currently requiring or likely to require diathermy